{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:56:46Z","timestamp":1793987806209,"version":"4.8.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background and Aims<\/jats:title><jats:p>Chitinase 3-like protein 1 (CHI3L1) is a marker of liver fibrosis produced mainly by hepatic macrophages. However, few studies have assessed the relationship between CHI3L1 and liver fibrosis in autoimmune liver diseases (AILDs). We aimed to explore the diagnostic value of CHI3L1 for liver fibrosis in AILDs and to compare its application differences between AILDs and chronic hepatitis B (CHB) patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The fibrotic group was defined as liver stiffness measurement (LSM) &amp;gt; 9.70kPa. Serum CHI3L1 levels were measured by ELISA in 78 AILDs patients, 65 chronic hepatitis B patients. The diagnostic accuracy was evaluated by the area under the receiver operating characteristic curve (AUROC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Serum CHI3L1 levels in AILDs patients were positively correlated with LSM (r=0.750, <jats:italic>p &amp;lt;<\/jats:italic>0.001). The AUROC for serum CHI3L1 in identifying significant liver fibrosis was 0.939 (95% CI: 0.891 - 0.988), which was higher than that of other non - invasive fibrosis scores (APRI, FIB - 4, GPR, AAR, NLP, and PLR). At the optimal cutoff value of 86.84 ng\/mL, the sensitivity and specificity were 92.9% and 83.3%, respectively. Furthermore, in patients with no significant difference in LSM, serum CHI3L1 levels were higher in the autoimmune liver disease group than in the CHB group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Serum CHI3L1 is an effective non-invasive indicator for assessing liver fibrosis in AILDs patients and may vary in different etiologies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1504066","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T05:23:00Z","timestamp":1745558580000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Chitinase 3-like protein 1: a diagnostic biomarker for early liver fibrosis in autoimmune liver diseases"],"prefix":"10.3389","volume":"16","author":[{"given":"Shafei","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conggao","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijia","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaonan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiahong","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1136\/gutjnl-2020-322362","article-title":"Recent advances in clinical practice: epidemiology of autoimmune liver diseases","volume":"70","author":"Trivedi","year":"2021","journal-title":"Gut"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2011.03.019","article-title":"Prevalence of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome","volume":"9","author":"Bonder","year":"2011","journal-title":"Clin gastroenterology hepatology: Off Clin Pract J Am Gastroenterological Association"},{"key":"B3","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.cgh.2020.05.061","article-title":"Trends in incidence of autoimmune liver diseases and increasing incidence of autoimmune hepatitis","volume":"19","author":"Lamba","year":"2021","journal-title":"Clin gastroenterology hepatology: Off Clin Pract J Am Gastroenterological Association"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(90)91167-5","article-title":"A 21-year experience with major hemorrhage after percutaneous liver biopsy","volume":"99","author":"McGill","year":"1990","journal-title":"Gastroenterology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2021-000701","article-title":"Value and risk of percutaneous liver biopsy in patients with cirrhosis and clinical suspicion of autoimmune hepatitis","volume":"8","author":"Sripongpun","year":"2021","journal-title":"BMJ Open gastroenterology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update","volume":"75","year":"2021","journal-title":"J hepatology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e22922","DOI":"10.1002\/jcla.22922","article-title":"Noninvasive indicators predict advanced liver fibrosis in autoimmune hepatitis patients","volume":"33","author":"Liu","year":"2019","journal-title":"J Clin Lab analysis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.v49.11","article-title":"Chitinase 3-like 1 deficiency ameliorates liver fibrosis by promoting hepatic macrophage apoptosis","volume":"49","author":"Higashiyama","year":"2019","journal-title":"Hepatology research: Off J Japan Soc Hepatology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1080\/10408363.2016.1190683","article-title":"Role of inflammatory marker YKL-40 in the diagnosis, prognosis and cause of cardiovascular and liver diseases","volume":"53","author":"Kjaergaard","year":"2016","journal-title":"Crit Rev Clin Lab Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-018-1136-2","article-title":"Serum YKL-40 as a biomarker for liver fibrosis in chronic hepatitis B patients with normal and mildly elevated ALT","volume":"46","author":"Yan","year":"2018","journal-title":"Infection"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12982","article-title":"Changes in serum chitinase 3-like 1 levels correlate with changes in liver fibrosis measured by two established quantitative methods in chronic hepatitis B patients following antiviral therapy","volume":"48","author":"Wang","year":"2018","journal-title":"Hepatology research: Off J Japan Soc Hepatology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.hbpd.2020.05.009","article-title":"Serum chitinase-3-like protein 1 is a biomarker of liver fibrosis in patients with chronic hepatitis B in China","volume":"19","author":"Jin","year":"2020","journal-title":"Hepatobiliary pancreatic Dis international: HBPD Int"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22322","article-title":"Simplified criteria for the diagnosis of autoimmune hepatitis","volume":"48","author":"Hennes","year":"2008","journal-title":"Hepatology (Baltimore Md)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis","volume":"67","year":"2017","journal-title":"J hepatology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/hep.510280203","article-title":"Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy","volume":"28","author":"Chazouill\u00e8res","year":"1998","journal-title":"Hepatology (Baltimore Md)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatology Int"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J\u00a0hepatology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2024.1411802","article-title":"Comparing similarities and differences between NAFLD, MAFLD, and MASLD in the general U.S. population","volume":"11","author":"Zou","year":"2024","journal-title":"Front Nutr"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v27.i7.641","article-title":"Effect of liver inflammation on accuracy of FibroScan device in assessing liver fibrosis stage in patients with chronic hepatitis B virus infection","volume":"27","author":"Huang","year":"2021","journal-title":"World J gastroenterology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.01.042","article-title":"Accuracy of fibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease","volume":"156","author":"Eddowes","year":"2019","journal-title":"Gastroenterology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.09.020","article-title":"Autoimmune liver disease, autoimmunity and liver transplantation","volume":"60","author":"Carbone","year":"2014","journal-title":"J hepatology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1016\/j.cgh.2020.10.006","article-title":"Increased mortality risk in autoimmune hepatitis: A nationwide population-based cohort study with histopathology","volume":"19","author":"Sharma","year":"2021","journal-title":"Clin gastroenterology hepatology: Off Clin Pract J Am Gastroenterological Association"},{"key":"B23","doi-asserted-by":"publisher","first-page":"111556","DOI":"10.1016\/j.fct.2020.111556","article-title":"The liver fibrosis niche: Novel insights into the interplay between fibrosis-composing mesenchymal cells, immune cells, endothelial cells, and extracellular matrix","volume":"143","author":"Matsuda","year":"2020","journal-title":"Food Chem toxicology: an Int J published Br Industrial Biol Res Association"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232012572","article-title":"The molecular mechanisms of liver fibrosis and its potential therapy in application","volume":"23","author":"Zhang","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B25","doi-asserted-by":"publisher","first-page":"110357","DOI":"10.1016\/j.intimp.2023.110357","article-title":"Macrophage in liver Fibrosis: Identities and mechanisms","volume":"120","author":"Wang","year":"2023","journal-title":"Int immunopharmacology"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/cells11091500","article-title":"Recent advancements in antifibrotic therapies for regression of liver fibrosis","volume":"11","author":"Jangra","year":"2022","journal-title":"Cells"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0676.2001.021004272.x","article-title":"Apoptotic pathways in primary biliary cirrhosis and autoimmune hepatitis","volume":"21","author":"Fox","year":"2001","journal-title":"Liver"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2004.11.023","article-title":"Markers of cell activation and apoptosis in bone marrow mononuclear cells of patients with autoimmune hepatitis type 1 and primary biliary cirrhosis","volume":"42","author":"Tsikrikoni","year":"2005","journal-title":"J hepatology"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1084\/jem.194.2.113","article-title":"Constitutively activated Akt-1 is vital for the survival of human monocyte-differentiated macrophages. Role of Mcl-1, independent of nuclear factor (NF)-kappaB, Bad, or caspase activation","volume":"194","author":"Liu","year":"2001","journal-title":"J Exp medicine"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(00)80095-1","article-title":"Serum YKL-40 is increased in patients with hepatic fibrosis","volume":"32","author":"Johansen","year":"2000","journal-title":"J hepatology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2017010110","article-title":"Breast Regression Protein-39\/Chitinase 3-Like 1 Promotes Renal Fibrosis after Kidney Injury via Activation of Myofibroblasts","volume":"28","author":"Montgomery","year":"2017","journal-title":"J Am Soc Nephrology: JASN"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2011.498","article-title":"Chitinase 3-like 1 promotes macrophage recruitment and angiogenesis in colorectal cancer","volume":"31","author":"Kawada","year":"2012","journal-title":"Oncogene"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242216149","article-title":"Potential roles and future perspectives of chitinase 3-like 1 in macrophage polarization and the development of diseases","volume":"24","author":"Zhao","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.15.5249","article-title":"Potential role of chitinase 3-like-1 in inflammation-associated carcinogenic changes of epithelial cells","volume":"15","author":"Eurich","year":"2009","journal-title":"World J gastroenterology"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2013.03.016","article-title":"Diverse pathological implications of YKL-40: answers may lie in \u2018outside-in\u2019 signaling","volume":"25","author":"Prakash","year":"2013","journal-title":"Cell signalling"},{"key":"B36","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41392-020-00303-7","article-title":"Chitinase-3 like-protein-1 function and its role in diseases","volume":"5","author":"Zhao","year":"2020","journal-title":"Signal transduction targeted Ther"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2009.08.024","article-title":"YKL-40 secreted from adipose tissue inhibits degradation of type I collagen","volume":"388","author":"Iwata","year":"2009","journal-title":"Biochem Biophys Res communications"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.04.006","article-title":"EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis","volume":"63","year":"2015","journal-title":"J hepatology"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1504066\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T05:23:00Z","timestamp":1745558580000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1504066\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":38,"alternative-id":["10.3389\/fimmu.2025.1504066"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1504066","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,25]]},"article-number":"1504066"}}